Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 51: 1512-1515, 2005; 10.1373/clinchem.2005.049841
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (13)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Herrmann, M.
Right arrow Articles by Herrmann, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Herrmann, M.
Right arrow Articles by Herrmann, W.
Related Collections
Right arrow Other Areas of Clinical Chemistry
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
(Clinical Chemistry. 2005;51:1512-1515.)
© 2005 American Association for Clinical Chemistry, Inc.


Technical Briefs

Relationship of Plasma Homocysteine with the Severity of Chronic Heart Failure

Markus Herrmann1, Ingrid Kindermann2, Stephanie Müller1, Thomas Georg3, Michael Kindermann2, Michael Böhm2 and Wolfgang Herrmann1,a

1 Abteilung für Klinische Chemie und Laboratoriumsmedizin/Zentrallabor,2 Klinik für Innere Medizin III, and3 Institut für Medizinische Biometrie, Epidemiologie und Medizinische Informatik, Universitätsklinikum des Saarland, Homburg/Saar, Germany;

aaddress correspondence to this author at: Abteilung für Klinische Chemie und Laboratoriumsmedizin/Zentrallabor, Universitätsklinikum des Saarland, D-66421 Homburg/Saar, Germany; fax 49-6841-1630703, e-mail kchwher@uniklinik-saarland.de

The first 20% of the full text of this article appears below.

Chronic heart failure (CHF) is a major public health problem causing considerable morbidity and mortality (1)(2)(3). Prevention of CHF by identifying risk factors is therefore a major issue. Previous studies found that hypertension, smoking, diabetes mellitus, obesity, and advancing age are the most important risk factors for CHF (4). Recently, plasma homocysteine (Hcy) has been suggested as a newly recognized risk factor (5)(6). However, there are no data regarding the association between Hcy and various objective as well as subjective measures of CHF. The demonstration of such relationships would help to clarify the role of hyperhomocysteinemia in CHF. We hypothesized that plasma Hcy is associated with clinical and echocardiographic signs of CHF as well as with N-terminal pro-brain natriuretic peptide (NT-proBNP), suggesting a relationship between Hcy and the severity of CHF. Accordingly, we investigated the relationships of plasma Hcy with serum NT-proBNP and clinical and echocardiographic indices of CHF in patients and in controls.

For this study, 95 patients with systolic CHF and 12 healthy persons without cardiac diseases were interviewed and examined by the same 2 experienced cardiologists, who were blinded to the study. All participants had a medical history, physical examination, venous blood sampling, 6-min walking test (6-MWT), electrocardiography, and echocardiography. Eighty-two patients underwent a cardiac catheterization according to the American Heart Association guidelines (7). Additionally, 37 patients performed a symptom-limited bicycle exercise test (Ergoline cardio-systems) with gas-exchange analysis (MedGraphics CPX/D spiroergometry system; Medical Graphics Corporation) to determine maximum oxygen uptake (VO2max). Informed consent was obtained from all participants, and the study protocol was approved by the Institutional Review Board.

Nonfasting venous blood samples (plasma and serum) were drawn during the office visits . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
K. S. Moshal, S. M. Tipparaju, T. P. Vacek, M. Kumar, M. Singh, I. E. Frank, P. K. Patibandla, N. Tyagi, J. Rai, N. Metreveli, et al.
Mitochondrial matrix metalloproteinase activation decreases myocyte contractility in hyperhomocysteinemia
Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H890 - H897.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
M. Herrmann, O. Taban-Shoma, U. Hubner, A. Pexa, H. Kilter, N. Umanskaya, R. Hans Straub, M. Bohm, and W. Herrmann
Hyperhomocysteinemia and Myocardial Expression of Brain Natriuretic Peptide in Rats
Clin. Chem., April 1, 2007; 53(4): 773 - 780.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
M. Herrmann, S. Muller, I. Kindermann, L. Gunther, J. Konig, M. Bohm, and W. Herrmann
Plasma B vitamins and their relation to the severity of chronic heart failure
Am. J. Clinical Nutrition, January 1, 2007; 85(1): 117 - 123.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.